Skip to main content
Erschienen in: Breast Cancer Research and Treatment 2/2011

01.11.2011 | Epidemiology

Effect of false-positives and women’s characteristics on long-term adherence to breast cancer screening

verfasst von: R. Román, M. Sala, M. De La Vega, C. Natal, J. Galceran, I. González-Román, A. Baroja, R. Zubizarreta, N. Ascunce, D. Salas, X. Castells

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 2/2011

Einloggen, um Zugang zu erhalten

Abstract

False-positive results may influence adherence to mammography screening. The effectiveness of breast cancer screening is closely related to adequate adherence among the target population. The objective of this study was to evaluate how false-positives and women’s characteristics affect the likelihood of reattendance at routine breast cancer screening in a sequence of routine screening invitations. We performed a retrospective cohort study of 1,371,218 women aged 45–69 years, eligible for the next routine screening, who underwent 4,545,346 screening mammograms from 1990 to 2006. We estimated the likelihood of attendance at seven sequential screening mammograms. Multilevel discrete time hazard models were used to estimate the effect of false-positive results on reattendance, and the odds ratios (OR) of non-attendance for the women’s personal characteristics studied. The overall reattendance rate at the second screening was 81.7% while at the seventh screening was 95.6%. At the second screening invitation reattendance among women with and without a false-positive mammogram was 79.3 vs. 85.3%, respectively. At the fourth and seventh screenings, these percentages were 86.3 vs. 89.9% and 94.6 vs. 96.0%, respectively. The study variables associated with a higher risk of failing to participate in subsequent screenings were oldest age (OR = 8.48; 95% CI: 8.31–8.65), not attending their first screening invitation (OR = 1.12; 95% CI: 1.11–1.14), and previous invasive procedures (OR = 1.09; 95% CI: 1.07–1.10). The risk of non-attendance was lower in women with a familial history of breast cancer (OR = 0.97; 95% CI: 0.96–0.99), and those using hormone replacement therapy (OR = 0.96; 95% CI: 0.94–0.97). In conclusion, reattendance was lower in women with false-positive mammograms than in those with negative results, although this difference decreased with the number of completed screening participations, suggesting that abnormal results in earlier screenings more strongly influence behavior. These findings may be useful in providing women with accurate information and in improving the effectiveness of screening programs.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Brett J, Bankhead C, Henderson B, Watson E, Austoker J (2005) The psychological impact of mammographic screening. A systematic review. Psychooncology 14:917–938PubMedCrossRef Brett J, Bankhead C, Henderson B, Watson E, Austoker J (2005) The psychological impact of mammographic screening. A systematic review. Psychooncology 14:917–938PubMedCrossRef
2.
Zurück zum Zitat Lerman C, Trock B, Rimer BK, Boyce A, Jepson C, Engstrom PF (1991) Psychological and behavioral implications of abnormal mammograms. Ann Intern Med 114:657–661PubMed Lerman C, Trock B, Rimer BK, Boyce A, Jepson C, Engstrom PF (1991) Psychological and behavioral implications of abnormal mammograms. Ann Intern Med 114:657–661PubMed
3.
Zurück zum Zitat Bull AR, Campbell MJ (1991) Assessment of the psychological impact of a breast screening programme. Br J Radiol 64:510–515PubMedCrossRef Bull AR, Campbell MJ (1991) Assessment of the psychological impact of a breast screening programme. Br J Radiol 64:510–515PubMedCrossRef
4.
Zurück zum Zitat Brewer NT, Salz T, Lillie SE (2007) Systematic review: the long-term effects of false-positive mammograms. Ann Intern Med 146:502–510PubMed Brewer NT, Salz T, Lillie SE (2007) Systematic review: the long-term effects of false-positive mammograms. Ann Intern Med 146:502–510PubMed
5.
Zurück zum Zitat Salz T, Defrank JT, Brewer NT (2011) False positive mammograms in Europe: do they affect reattendance? Breast Cancer Res Treat 127:229–230PubMedCrossRef Salz T, Defrank JT, Brewer NT (2011) False positive mammograms in Europe: do they affect reattendance? Breast Cancer Res Treat 127:229–230PubMedCrossRef
6.
Zurück zum Zitat Day NE, Williams DR, Khaw KT (1989) Breast cancer screening programmes: the development of a monitoring and evaluation system. Br J Cancer 59:954–958PubMedCrossRef Day NE, Williams DR, Khaw KT (1989) Breast cancer screening programmes: the development of a monitoring and evaluation system. Br J Cancer 59:954–958PubMedCrossRef
7.
Zurück zum Zitat Chiarelli AM, Moravan V, Halapy E, Majpruz V, Mai V, Tatla RK (2003) False-positive result and reattendance in the Ontario Breast Screening Program. J Med Screen 10:129–133PubMedCrossRef Chiarelli AM, Moravan V, Halapy E, Majpruz V, Mai V, Tatla RK (2003) False-positive result and reattendance in the Ontario Breast Screening Program. J Med Screen 10:129–133PubMedCrossRef
8.
Zurück zum Zitat Hofvind S, Wang H, Thoresen S (2003) The Norwegian Breast Cancer Screening Program: re-attendance related to the women’s experiences, intentions and previous screening result. Cancer Causes Control 14:391–398PubMedCrossRef Hofvind S, Wang H, Thoresen S (2003) The Norwegian Breast Cancer Screening Program: re-attendance related to the women’s experiences, intentions and previous screening result. Cancer Causes Control 14:391–398PubMedCrossRef
9.
Zurück zum Zitat Johnson MM, Hislop TG, Kan L, Coldman AJ, Lai A (1996) Compliance with the screening mammography program of British Columbia: will she return? Can J Public Health 87:176–180PubMed Johnson MM, Hislop TG, Kan L, Coldman AJ, Lai A (1996) Compliance with the screening mammography program of British Columbia: will she return? Can J Public Health 87:176–180PubMed
10.
Zurück zum Zitat McCann J, Stockton D, Godward S (2002) Impact of false-positive mammography on subsequent screening attendance and risk of cancer. Breast Cancer Res 4:R11PubMedCrossRef McCann J, Stockton D, Godward S (2002) Impact of false-positive mammography on subsequent screening attendance and risk of cancer. Breast Cancer Res 4:R11PubMedCrossRef
11.
Zurück zum Zitat Brett J, Austoker J (2001) Women who are recalled for further investigation for breast screening: psychological consequences 3 years after recall and factors affecting re-attendance. J Public Health Med 23:292–300PubMedCrossRef Brett J, Austoker J (2001) Women who are recalled for further investigation for breast screening: psychological consequences 3 years after recall and factors affecting re-attendance. J Public Health Med 23:292–300PubMedCrossRef
12.
Zurück zum Zitat Lampic C, Thurfjell E, Sjoden PO (2003) The influence of a false-positive mammogram on a woman’s subsequent behaviour for detecting breast cancer. Eur J Cancer 39:1730–1737PubMedCrossRef Lampic C, Thurfjell E, Sjoden PO (2003) The influence of a false-positive mammogram on a woman’s subsequent behaviour for detecting breast cancer. Eur J Cancer 39:1730–1737PubMedCrossRef
13.
Zurück zum Zitat O’Sullivan I, Sutton S, Dixon S, Perry N (2001) False positive results do not have a negative effect on reattendance for subsequent breast screening. J Med Screen 8:145–148PubMedCrossRef O’Sullivan I, Sutton S, Dixon S, Perry N (2001) False positive results do not have a negative effect on reattendance for subsequent breast screening. J Med Screen 8:145–148PubMedCrossRef
14.
Zurück zum Zitat Pinckney RG, Geller BM, Burman M, Littenberg B (2003) Effect of false-positive mammograms on return for subsequent screening mammography. Am J Med 114:120–125PubMedCrossRef Pinckney RG, Geller BM, Burman M, Littenberg B (2003) Effect of false-positive mammograms on return for subsequent screening mammography. Am J Med 114:120–125PubMedCrossRef
15.
Zurück zum Zitat Lipkus IM, Halabi S, Strigo TS, Rimer BK (2000) The impact of abnormal mammograms on psychosocial outcomes and subsequent screening. Psychooncology 9:402–410PubMedCrossRef Lipkus IM, Halabi S, Strigo TS, Rimer BK (2000) The impact of abnormal mammograms on psychosocial outcomes and subsequent screening. Psychooncology 9:402–410PubMedCrossRef
16.
Zurück zum Zitat Burman ML, Taplin SH, Herta DF, Elmore JG (1999) Effect of false-positive mammograms on interval breast cancer screening in a health maintenance organization. Ann Intern Med 131:1–6PubMed Burman ML, Taplin SH, Herta DF, Elmore JG (1999) Effect of false-positive mammograms on interval breast cancer screening in a health maintenance organization. Ann Intern Med 131:1–6PubMed
17.
Zurück zum Zitat Perry N, Broeders M, de Wolf C, Törnberg S, Holland R, von Karsa L (2006) European guidelines for quality assurance in breast cancer screening and diagnosis. Office for Official Publications of the European Communities, Luxenburg Perry N, Broeders M, de Wolf C, Törnberg S, Holland R, von Karsa L (2006) European guidelines for quality assurance in breast cancer screening and diagnosis. Office for Official Publications of the European Communities, Luxenburg
18.
Zurück zum Zitat Bulliard JL, De Landtsheer JP, Levi F (2004) Reattendance in the Swiss mammography screening pilot programme. J Med Screen 11:59–64PubMedCrossRef Bulliard JL, De Landtsheer JP, Levi F (2004) Reattendance in the Swiss mammography screening pilot programme. J Med Screen 11:59–64PubMedCrossRef
19.
Zurück zum Zitat Assembly of Members (2001) CONSTITUTION AND BYLAWS of the European Breast Cancer Network Assembly of Members (2001) CONSTITUTION AND BYLAWS of the European Breast Cancer Network
20.
Zurück zum Zitat Roman R, Sala M, Salas D, Ascunce N, Zubizarreta R, Castells X (2011) Effect of protocol-related variables and women’s characteristics on the cumulative false-positive risk in breast cancer screening. Ann Oncol. doi:10.1093/annonc/mdr032 Roman R, Sala M, Salas D, Ascunce N, Zubizarreta R, Castells X (2011) Effect of protocol-related variables and women’s characteristics on the cumulative false-positive risk in breast cancer screening. Ann Oncol. doi:10.​1093/​annonc/​mdr032
21.
Zurück zum Zitat Ascunce N, Salas D, Zubizarreta R, Almazan R, Ibanez J, Ederra M (2010) Cancer screening in Spain. Ann Oncol 21(Suppl 3):iii43–iii51PubMedCrossRef Ascunce N, Salas D, Zubizarreta R, Almazan R, Ibanez J, Ederra M (2010) Cancer screening in Spain. Ann Oncol 21(Suppl 3):iii43–iii51PubMedCrossRef
22.
Zurück zum Zitat Singer J, Willett JB (2003) Fitting basic discrete-time hazard models. Applied longitudinal data analysis: modelling change and event occurrence. Oxford University Press, New York, pp 357–467 Singer J, Willett JB (2003) Fitting basic discrete-time hazard models. Applied longitudinal data analysis: modelling change and event occurrence. Oxford University Press, New York, pp 357–467
23.
Zurück zum Zitat Willett JB, Singer J (1995) It’s deja vu all over again: using multiple-spell discrete-time survival analysis. J Educ Behav Stat 20(1):41–67 Willett JB, Singer J (1995) It’s deja vu all over again: using multiple-spell discrete-time survival analysis. J Educ Behav Stat 20(1):41–67
24.
Zurück zum Zitat Álamo-Junquera D, Murta-Nascimento C, Macià F, Baré M, Galceran J, Ascunce N et al (2011) Effect of false-positive results on reattendance at breast cancer screening programmes in Spain. Eur J Public Health. doi:10.1093/eurpub/ckr057 Álamo-Junquera D, Murta-Nascimento C, Macià F, Baré M, Galceran J, Ascunce N et al (2011) Effect of false-positive results on reattendance at breast cancer screening programmes in Spain. Eur J Public Health. doi:10.​1093/​eurpub/​ckr057
25.
Zurück zum Zitat Pisano ED, Earp J, Schell M, Vokaty K, Denham A (1998) Screening behavior of women after a false-positive mammogram. Radiology 208:245–249PubMed Pisano ED, Earp J, Schell M, Vokaty K, Denham A (1998) Screening behavior of women after a false-positive mammogram. Radiology 208:245–249PubMed
26.
Zurück zum Zitat Hofvind S, Vacek PM, Skelly J, Weaver DL, Geller BM (2008) Comparing screening mammography for early breast cancer detection in Vermont and Norway. J Natl Cancer Inst 100:1082–1091PubMedCrossRef Hofvind S, Vacek PM, Skelly J, Weaver DL, Geller BM (2008) Comparing screening mammography for early breast cancer detection in Vermont and Norway. J Natl Cancer Inst 100:1082–1091PubMedCrossRef
27.
Zurück zum Zitat Smith-Bindman R, Ballard-Barbash R, Miglioretti DL, Patnick J, Kerlikowske K (2005) Comparing the performance of mammography screening in the USA and the UK. J Med Screen 12:50–54PubMedCrossRef Smith-Bindman R, Ballard-Barbash R, Miglioretti DL, Patnick J, Kerlikowske K (2005) Comparing the performance of mammography screening in the USA and the UK. J Med Screen 12:50–54PubMedCrossRef
28.
Zurück zum Zitat Elmore JG, Nakano CY, Koepsell TD, Desnick LM, D’Orsi CJ, Ransohoff DF (2003) International variation in screening mammography interpretations in community-based programs. J Natl Cancer Inst 95:1384–1393PubMed Elmore JG, Nakano CY, Koepsell TD, Desnick LM, D’Orsi CJ, Ransohoff DF (2003) International variation in screening mammography interpretations in community-based programs. J Natl Cancer Inst 95:1384–1393PubMed
29.
Zurück zum Zitat Yankaskas BC, Klabunde CN, Ancelle-Park R, Renner G, Wang H, Fracheboud J et al (2004) International comparison of performance measures for screening mammography: can it be done? J Med Screen 11:187–193PubMedCrossRef Yankaskas BC, Klabunde CN, Ancelle-Park R, Renner G, Wang H, Fracheboud J et al (2004) International comparison of performance measures for screening mammography: can it be done? J Med Screen 11:187–193PubMedCrossRef
30.
Zurück zum Zitat Castells X, Molins E, Macia F (2006) Cumulative false positive recall rate and association with participant related factors in a population based breast cancer screening programme. J Epidemiol Community Health 60:316–321PubMedCrossRef Castells X, Molins E, Macia F (2006) Cumulative false positive recall rate and association with participant related factors in a population based breast cancer screening programme. J Epidemiol Community Health 60:316–321PubMedCrossRef
31.
Zurück zum Zitat Elmore JG, Barton MB, Moceri VM, Polk S, Arena PJ, Fletcher SW (1998) Ten-year risk of false positive screening mammograms and clinical breast examinations. N Engl J Med 338:1089–1096PubMedCrossRef Elmore JG, Barton MB, Moceri VM, Polk S, Arena PJ, Fletcher SW (1998) Ten-year risk of false positive screening mammograms and clinical breast examinations. N Engl J Med 338:1089–1096PubMedCrossRef
32.
Zurück zum Zitat Hofvind S, Thoresen S, Tretli S (2004) The cumulative risk of a false-positive recall in the Norwegian Breast Cancer Screening Program. Cancer 101:1501–1507PubMedCrossRef Hofvind S, Thoresen S, Tretli S (2004) The cumulative risk of a false-positive recall in the Norwegian Breast Cancer Screening Program. Cancer 101:1501–1507PubMedCrossRef
33.
Zurück zum Zitat Rodriguez C, Plasencia A, Schroeder DG (1995) Predictive factors of enrollment and adherence in a breast cancer screening program in Barcelona (Spain). Soc Sci Med 40:1155–1160PubMedCrossRef Rodriguez C, Plasencia A, Schroeder DG (1995) Predictive factors of enrollment and adherence in a breast cancer screening program in Barcelona (Spain). Soc Sci Med 40:1155–1160PubMedCrossRef
34.
Zurück zum Zitat de Waard F, Collette HJ, Rombach JJ, Baanders-van Halewijn EA, Honing C (1984) The DOM project for the early detection of breast cancer, Utrecht, The Netherlands. J Chronic Dis 37:1–44PubMedCrossRef de Waard F, Collette HJ, Rombach JJ, Baanders-van Halewijn EA, Honing C (1984) The DOM project for the early detection of breast cancer, Utrecht, The Netherlands. J Chronic Dis 37:1–44PubMedCrossRef
35.
Zurück zum Zitat Cockburn J, Schofield P, White V, Hill D, Russell I (1997) Predictors of returning for second round screening at a population based mammographic screening programme in Melbourne, Australia. J Epidemiol Community Health 51:62–66PubMedCrossRef Cockburn J, Schofield P, White V, Hill D, Russell I (1997) Predictors of returning for second round screening at a population based mammographic screening programme in Melbourne, Australia. J Epidemiol Community Health 51:62–66PubMedCrossRef
36.
Zurück zum Zitat Sutton S, Bickler G, Sancho-Aldridge J, Saidi G (1994) Prospective study of predictors of attendance for breast screening in inner London. J Epidemiol Community Health 48:65–73PubMedCrossRef Sutton S, Bickler G, Sancho-Aldridge J, Saidi G (1994) Prospective study of predictors of attendance for breast screening in inner London. J Epidemiol Community Health 48:65–73PubMedCrossRef
Metadaten
Titel
Effect of false-positives and women’s characteristics on long-term adherence to breast cancer screening
verfasst von
R. Román
M. Sala
M. De La Vega
C. Natal
J. Galceran
I. González-Román
A. Baroja
R. Zubizarreta
N. Ascunce
D. Salas
X. Castells
Publikationsdatum
01.11.2011
Verlag
Springer US
Erschienen in
Breast Cancer Research and Treatment / Ausgabe 2/2011
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-011-1581-4

Weitere Artikel der Ausgabe 2/2011

Breast Cancer Research and Treatment 2/2011 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.